Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Abstract: A bamboo charcoal powder-based false eyelash is obtained by evenly mixing 90-96% of polyester particles, 3-8% of bamboo charcoal powder and 1-2% of adjuvant, subsequently hot melting, wire drawing and forming and then cooling. The false eyelash can be subjected to not only chemical sharpening tip but also physical sharpening tip, has greatly reduced weight and is environmental-friendly; an organosilicon quaternary ammonium salt structure and three chlorine atoms in the adjuvant synergistically take antibacterial effects, and a long carbon chain further enhances an antibacterial effect.

Abstract: The present invention is directed to a nanoparticle or microparticle for binding to the surface of a cell, wherein the nanoparticle or microparticle comprises (i) multiple different ligand types on its external surface which are capable of binding to different respective receptor types on said cell surface, and (ii) a polymer brush on its external surface. The present invention is further directed to pharmaceutical compositions comprising a plurality of nanoparticles or microparticles of the invention, medical uses of such nanoparticles or microparticles, and a vaccine comprising such nanoparticles or microparticles.

Abstract: Embodiments of the present invention relate to mechanically-activated microcapsules (MAMCs) for controlled drug-delivery, wherein the MAMCs release one or more active ingredients in response to mechanical stimuli in a subject's body. The MAMCs provide a platform for stimulating biological regeneration, biological repair, modifying disease, and/or controlling disease in mechanically-loaded musculoskeletal tissues.

Abstract: The invention relates to a nanostructured lipid gel formed by alternating layers and vesicles composed of phospholipids, fatty acids and a high water content. The structure and fluidity respond reversibly to temperature and pH, and they are capable of transporting at least one active ingredient within the skin and also to the follicles. The exclusively lipid composition ensures high biocompatibility, and the rheological behaviour facilitates topical and ocular application.

Abstract: Methods for applying a sphingolipid aggregate coating to a surface of a substrate for inhibition and prevention of biofilm growth, methods for inhibiting and preventing biofilms, biofilm-inhibiting coatings and coated devices are provided. Coating processes include suspending an amount of sphingolipid in a medium-to-fast-evaporating organic solvent; b) applying energy to the suspension sufficient to create a colloidal dispersion of sphingolipid in the solvent; c) heating the dispersion sufficient to create a solution; and d) coating the surface of the substrate with at least one application of solution, each application followed directly by a complete solvent evaporation period. The resulting coatings exhibit aggregate architectures particularly effective for inhibition and prevention of biofilms.

Abstract: The invention relates to a cosmetic process for treating keratin fibres, comprising: (i) a step of applying to the keratin fibres a cosmetic composition containing a polyvinyl alcohol polymer comprising:—an alcohol unit—optionally an acetate unit—a photocrosslinkable unit—a hydrophobic unit; (ii) a step of irradiating the composition on the keratin fibres to crosslink said polymer. The invention also relates to the novel polyvinyl alcohol polymer used in said process. The treated keratin fibres have good cosmetic properties in terms of a soft feel and disentangling, which properties are persistent after one or more shampoo washes.

Abstract: A multi-phase oral composition for whitening teeth.

Abstract: Disclosed herein are a microbubble-extracellular vesicle complex, a production method therefor, and a system for driving the same. In one aspect, preferred microbubble-extracellular vesicle complexes may comprise an ultrasound contrast agent-based microbubble, an extracellular cell derived from a natural killer cell (NK cell), a human glial cell, or a human mesenchymal stem cell, and a coupling medium and can be derive in a 3D mode using ultrasonic waves and deliver a drug loaded in the extracellular vesicle to a target site.

Abstract: The present invention provides, inter alia, methods, kits, and pharmaceutical compositions for treating or ameliorating the effects of a cancer in a subject in need thereof. The method comprises administering to the subject an effective amount of (i) a first anti-cancer agent, which is BVD-523 or a pharmaceutically acceptable salt thereof and (ii) a second anti-cancer agent, which is a CDK inhibitor or a pharmaceutically acceptable salt thereof, to treat or ameliorate the effects of the cancer. Additional methods for effecting cancer cell death are also provided.

Abstract: This invention provides polymer particles which contain negative charges on the surface of the particle. Preferably, the particles comprise PLGA and sulfate polymer. The invention also provides polymer particle produced by the methods of the invention.

Abstract: The present disclosure generally describes an antimicrobial composition comprising: a water solution comprising a chlorite salt and/or chlorine dioxide having a concentration ranging from about 2,000 parts per million to about 8,000 parts per million, and at least one quaternary ammonium salt having a concentration ranging from about 5,000 parts per million to about 10,000 parts per million. The present compositions are advantageously effective against a variety of bacteria, viruses, molds, and fungi, and may be used in a variety applications. Such applications include, without limitation, healthcare setting and equipment disinfection, food surface disinfection, agricultural disinfection, and personal hand care disinfection.

Abstract: The present invention relates to a pharmaceutical composition for diagnosing and treating prostate cancer, capable of targeting PSMA, and a compound provided by one aspect of the present invention has a glutamine-urea-lysine compound to which a radioactive metal-coupled chelator is structurally coupled and to which an aryl group that can additionally bind to PSMA protein is coupled. Coupling between the glutamine-urea-lysine compound and the chelator includes a polar spacer so as to serve the role of reducing in vivo nonspecific coupling and exhibit an effect of being rapidly removed from vital organs, but not from prostate cancer. These characteristics lower the radiation exposure, which is caused by a therapeutic radioisotope-coupled compound, to normal tissue and organs, and thus reduce side effects. In addition, a compound that contains a phenyl group having a coupling force with albumin has an increased residence time in the blood, thereby becoming more accumulated in prostate cancer.

Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.

Abstract: The present chitosan-based superfine fiber invention relates to compositions, formulations, and processes that result in numerous significant advantages for the production and use of superfine fiber bioactive matrices in biomedical applications. The present invention relates to superfine, chitosan-based fibers, wherein the chitosan-based fibers have a percentage chitosan content of at least about 20% w/w, and highly conformable and compliant matrices comprising such fibers, processes for their production, and related formulations. The superfine chitosan-based fibers of the invention preferably include microfibers with diameter less than or equal to about 10 microns and micron and submicron fibers that are about 2 microns and less.

Abstract: One or more techniques and/or systems are disclosed for a method of administering a composition of an orally administered agent devised to provide desirable nutrients and other supplements to the body, which may help mitigate degradation of the skin, and may help promote the health of the skin, and/or treatment of skin conditions. The composition can comprise ingredients of a selected type, amount, and source, which, in this particular arrangement, may promote healthy skin and improve skin condition in a person. A composition that promotes healthy skin can comprise vitamin A; vitamin C; vitamin E; vitamin B6; zinc; rose hip extract; copper; and vitamin B3.

Abstract: Disclosed herein are low density particles comprising polymerized fibrin that are micrometer or nanometer sized in diameter. The particles can further include at least one therapeutic agent. The particles may be used to treat wounds, by administration directly or systemically to the site of the wound. Exemplary wounds that may be treated with the fibrin particles include a trauma wound, a surgical wound, a burn wound, or an ulcer wound. Also disclosed herein are methods for preparing the particles using a shearing process.

Abstract: A method of treating a fungal infection in a subject includes topically administering to the subject a therapeutically effective amount of a fungal iron acquisition inhibitor to treat fungal infection in the subject.

Abstract: Provided is a topical pharmaceutical gel composition of an amlodipine salt and methods for its use in the treatment of anorectal disease.

Abstract: Formulated and/or co-formulated liposomes comprising TLR prodrugs and/or TLR Lipid Moieties and methods of making the liposomes are disclosed herein. The TLR prodrug compositions comprise a drug moiety, a lipid moiety, and linkage unit that inhibit Toll-Like Receptor (e.g., TLR1/2, TLR4, and/or TLR7). The TLR prodrugs can be formulated and/or co-formulated into a liposome to provide a method of treating cancer, immunological disorders, and other disease by utilizing a targeted drug delivery vehicle.